Inhibrx Biosciences’ antibody ozekibart has notched a key phase 2 win in a rare bone cancer that currently has no approved treatments, prompting the San Diego biotech to plot a submission to the FDA in the second half of 2026.
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
